Recommendations on the use of ruxolitinib for the treatment of myelofibrosis

References

• Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87(1):25–33. doi: 10.1016/j.mayocp.2011.11.001
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:211. doi: 10.1186/s12885-016-2208-2
   PubMed Web of Science ®Google Scholar
• Harrison C, Mesa R, Ross D, et al. Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol. 2013;6(5):511–523. doi: 10.1586/17474086.2013.827413
   PubMed Web of Science ®Google Scholar
• Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(9):915–925. doi: 10.1002/ajh.23703
   PubMed Web of Science ®Google Scholar
• Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia. 2008;22(10):1813–1817. doi: 10.1038/leu.2008.229
   PubMed Web of Science ®Google Scholar
• O'Sullivan JM, Harrison CN. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms. Mol Cell Endocrinol. 2017. doi: 10.1016/j.mce.2017.1001.1050
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737–740. doi: 10.1016/j.leukres.2006.12.002
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–2901. doi: 10.1182/blood-2008-07-170449
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–1708. doi: 10.1182/blood-2009-09-245837
   PubMed Web of Science ®Google Scholar
• Devos T, Zachee P, Bron D, et al. Myelofibrosis patients in Belgium: disease characteristics. Acta Clin Belg. 2015;70(2):105–111. doi: 10.1179/2295333714Y.0000000097
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Bredeson C, Farnia S, et al. Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all Age groups. Biol Blood Marrow Transplant. 2015;21(11):1883–1887. doi: 10.1016/j.bbmt.2015.09.005
   PubMed Web of Science ®Google Scholar
• Farhadfar N, Cerquozzi S, Patnaik M, et al. Allogeneic hematopoietic stem-cell transplantation for myelofibrosis: a practical review. J Oncol Pract. 2016;12(7):611–621. doi: 10.1200/JOP.2016.013268
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Stalbovskaya V, Gopalakrishna P, et al. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leuk Lymphoma. 2016;57(10):2464–2467. doi: 10.3109/10428194.2016.1146950
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use assessment report – Jakavi. [cited 2017 Mar 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002464/WC500133226.pdf
   Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798. doi: 10.1056/NEJMoa1110556
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. doi: 10.1056/NEJMoa1110557
   PubMed Web of Science ®Google Scholar
• Yi CA, Tam CS, Verstovsek S. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol. 2015;11(5):719–733. doi: 10.2217/fon.14.272
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Gupta V, Gotlib J, et al. Pooled overall survival analysis of 5-year data from the COMFORT-I and COMFORT-II trials of ruxolitinib for the treatment of myelofibrosis (Abstract #3110). 58th Meeting & Exposition of the American Society of Hematology, San Diego, CA, United States; 2–6 December, 2016.
   Google Scholar
• Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29(11):2126–2133. doi: 10.1038/leu.2015.233
   PubMed Web of Science ®Google Scholar
• Institut National d'Assurance Maladie-Invalidité (INAMI). Spécialités pharmaceutiques – Liste – Chapter IV - 01/05/2017 – Lijst – Farmaceutische specialiteiten. [cited 2017 May 3]. Available from: http://www.inami.fgov.be/SiteCollectionDocuments/liste-specialites-chapter4-20170501.pdf
   Google Scholar
• Harrison CN, Talpaz M, Mead AJ. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. Leuk Lymphoma. 2016;57(10):2259–2267. doi: 10.1080/10428194.2016.1195501
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016;101(9):1065–1073. doi: 10.3324/haematol.2016.143677
   PubMed Web of Science ®Google Scholar
• Mead AJ, Milojkovic D, Knapper S, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol. 2015;170(1):29–39. doi: 10.1111/bjh.13379
   PubMed Web of Science ®Google Scholar
• Mesa R, Jamieson C, Bhatia R, et al. Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(12):1572–1611. doi: 10.6004/jnccn.2016.0169
   PubMedGoogle Scholar
• Marchetti M, Barosi G, Cervantes F, et al. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia. 2017;31(4):882–888. doi: 10.1038/leu.2016.283
   PubMed Web of Science ®Google Scholar
• Novartis Oncology. Paper version of the MPN10 Symptom Tracker; MPN10 Know your score. [cited 2017 May 3]/ Available from: http://jakavimicrosite.prod.novartis.episerverhosting.com/globalassets/site-components12/oncology/micro-jakavi/images/g-2014-inc-mpn_mpn10-symptom-form1.pdf
   Google Scholar
• Verstovsek S. Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. Leuk Lymphoma. 2014;55(1):5–6. doi: 10.3109/10428194.2013.802318
   PubMed Web of Science ®Google Scholar
• Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790–797. doi: 10.1182/blood-2015-03-633404
   PubMed Web of Science ®Google Scholar
• Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714–3719. doi: 10.1182/blood-2014-03-530865
   PubMed Web of Science ®Google Scholar
• Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680–692. doi: 10.1182/blood-2016-10-695957
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861–1869. doi: 10.1038/leu.2013.119
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28(9):1804–1810. doi: 10.1038/leu.2014.76
   PubMed Web of Science ®Google Scholar
• Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013;6(1):81. doi: 10.1186/1756-8722-6-81
   PubMed Web of Science ®Google Scholar
• Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013;6:79. doi: 10.1186/1756-8722-6-79
   PubMed Web of Science ®Google Scholar
• Centre Belge d'Information Pharmacothérapeutique (CBIP). Répertoire commenté des médicaments. [cited 2017 Mar 24]. Available from: http://www.cbip.be/fr/chapters/14?frag=13227&trade_family=13821
   Google Scholar
• European Medicines Agency (EMA). Jakavi: EPAR – Product Information. Annex 1: Summary of product characteristics. [cited 2017 Mar 2017]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002464/WC500133223.pdf. Last updated on Januray 25, 2017
   Google Scholar
• Chen X, Shi JG, Emm T, et al. Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients. Clin Pharmacol Drug Dev. 2014;3(1):34–42. doi: 10.1002/cpdd.77
   PubMed Web of Science ®Google Scholar
• Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. 2012;52(6):809–818. doi: 10.1177/0091270011405663
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–1127. doi: 10.1056/NEJMoa1002028
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Gotlib J, Gupta V, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013;7:13–21. doi: 10.2147/OTT.S53348
   PubMed Web of Science ®Google Scholar
• Gupta V, Harrison C, Hexner EO, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016;101(12):e482–e484. doi: 10.3324/haematol.2016.151449
   PubMed Web of Science ®Google Scholar
• McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4:2895. doi: 10.1186/s40164-015-0021-2
   Google Scholar
• Reilly JT, McMullin MF, Beer PA, et al. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol. 2014;167(3):418–420. doi: 10.1111/bjh.12985
   PubMed Web of Science ®Google Scholar
• Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17):2635–2642. doi: 10.1182/blood-2014-07-575373
   PubMed Web of Science ®Google Scholar
• Harrison CN, Mesa RA, Kiladjian JJ, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013;162(2):229–239. doi: 10.1111/bjh.12375
   PubMed Web of Science ®Google Scholar
• Tabarroki A, Lindner D, Visconte V, et al. Modified dose escalation of ruxolitinib: a feasible therapeutic approach in the management of myelofibrosis. Blood. 2013;122(21):1586–1586.
   Web of Science ®Google Scholar
• Foltz L, Palumbo GA, Martino B, et al. Safety and efficacy of ruxolitinib for the final enrollment of JUMP: an open-label, multicenter, single-arm, expanded-access study in patients with myelofibrosis (N = 2233). Blood. 2016;128(22):3107–3107.
   Web of Science ®Google Scholar
• Pardanani A, Tefferi A. Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J. 2014;4:e268. doi: 10.1038/bcj.2014.84
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479–488. doi: 10.3324/haematol.2014.115840
   PubMed Web of Science ®Google Scholar
• Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122(23):3843–3844. doi: 10.1182/blood-2013-10-531103
   PubMed Web of Science ®Google Scholar
• Polverelli N, Breccia M, Benevolo G, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol. 2017;92(1):37–41. doi: 10.1002/ajh.24572
   PubMed Web of Science ®Google Scholar
• Mesa RA, Komrokji RS, Verstovsek S. Ruxolitinib dose management as a key to long-term treatment success. Int J Hematol. 2016;104(4):420–429. doi: 10.1007/s12185-016-2084-1
   PubMed Web of Science ®Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–4053. doi: 10.1182/blood-2013-02-485888
   PubMed Web of Science ®Google Scholar